BALTIMORE (Stockpickr) -- Put down the 10-K filings and the stock screeners. It's time to take a break from the traditional methods of generating investment ideas. Instead, let the crowd do it for you.

From hedge funds to individual investors, scores of market participants are turning to social media to figure out which stocks are worth watching. It's a concept that's known as "crowdsourcing," and it uses the masses to identify emerging trends in the market.

Crowdsourcing has long been a popular tool for the advertising industry, but it also makes a lot of sense as an investment tool. After all, the market is completely driven by the supply and demand, so it can be valuable to see what names are trending among the crowd.

While some fund managers are already trying to leverage social media resources like Twitter to find algorithmic trading opportunities, for most investors, crowdsourcing works best as a starting point for investors who want a starting point in their analysis.

Today, we'll leverage the power of the crowd to take a look at some of the most active stocks on the market today.

Orexigen Therapeutics

Nearest Resistance: $8.50
Nearest Support: $6
Catalyst: FDA Comments

Today's trading session is looking pretty ugly for small-cap biopharmaceutical stock Orexigen Therapeutics (OREX) . Shares are down more than 13% this afternoon, following a Forbesstory published after the bell yesterday that quoted an FDA official as saying that OREX's recent positive study results were "unreliable," "misleading" and "likely false." The FDA comments are a big blow to OREX, which broke out at the start of March on the bullish study results.

So far, OREX hasn't given back all of its gains. Instead, it's throwing back to retest support at $6. For traders trying to play this setup, there's a lot of event risk surrounding the study. That makes buying OREX more of a lottery ticket than a high-probability trade.

Itau Unibanco

Nearest Resistance: $12.75
Nearest Support: $11.50
Catalyst: Merger

Speculation that Itau Unibanco (ITUB) - Get Report may have to undergo a public tender offer to complete a merger with Corpbanca spurred a 3.7% drop in shares Friday afternoon. While ITUB said that it won't need to clear that hurdle to close its merger between its Chilean subsidiary and Corpbanca, the announcement that regulators will ultimately get to make that decision adds some uncertainty that's being priced into shares today.

The selling in ITUB is getting exacerbated by rough-looking technical this afternoon. ITUB has been selling off lately, moving down in a descending triangle pattern since the calendar flipped to 2015. The breakdown level to watch here is $11.50. If that level gets violated in ITUB, look out below.

Barrick Gold

Nearest Resistance: $13
Nearest Support: $10
Catalyst: Spot Gold Drop

$14 billion gold miner Barrick Gold (ABX) is selling off more than 6% this afternoon thanks to a decline in spot gold prices. While spot is off less than half that amount today, the leveraged nature of miners means that Barrick is a higher-beta reaction to any move that gold prices make. That's not a particularly welcome bit of news considering the fact that ABX has given back 44% of its market value in the last 12 months,

While Barrick had been looking "bottomy" from a technical standpoint, the inverse head and shoulders pattern never triggered by moving through $13. Instead, shares are threatening to put the kibosh on a bottom by moving below $12. Put simply, I'd avoid being long ABX unless it's able to catch a bid above $13 again.

Advanced Micro Devices

Nearest Resistance: $3
Nearest Support: $2.60
Catalyst: Technical Setup

Chipmaker Advanced Micro Devices (AMD) - Get Report is getting shoved almost 3% lower on big volume this afternoon, swatted down for technical reasons after a less-than-auspicious start to the week. Shares violated $3 support on yesterday's close, and sellers are following through in today's session.

Support at $2.60 looks pretty week here, and it makes sense to avoid going long AMD unless you're an experienced trader. This stock has been volatile at a time when peers have held up relatively well.

Author had no positions in stocks mentioned.